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Abstract 
Background: Microscopy has long been considered to be the gold standard for diagnosis of malaria despite the 
introduction of newer assays. However, it has many challenges like requirement of trained microscopists and logistic 
issues. A vision based device that can diagnose malaria, provide speciation and estimate parasitaemia was evaluated.
Methods: The device was evaluated using samples from 431 consented patients, 361 of which were initially 
screened by RDT and microscopy and later analysed by PCR. It was a prospective, non‑randomized, blinded trial. 
Quantification of parasitaemia was performed by two experienced technicians. Samples were subjected to diagnosis 
by Sight Dx digital imaging scanning.
Results: The sensitivity and specificity of the SightDx P1 device for analysed samples were found to be 97.05 and 
96.33 %, respectively, when compared to PCR. When compared to microscopy, sensitivity and specificity were found 
to be 94.4 and 95.6 %, respectively. The device was able to speciate 73.3 % of the PCR Plasmodium falciparum positive 
samples and 91.4 % of PCR Plasmodium vivax positive samples.
Conclusion: The ability of the device to detect parasitaemia as compared with microscopy, was within 50 % in 
71.3 % of cases and demonstrated a correlation coefficient of 0.89.
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Background
According to the World Health Organization (WHO) 
estimates, there were ~207 million cases and 627,000 
deaths due to malaria in 2012 [1]. Half of the world’s pop-
ulation is at risk of being infected by malaria. Definitive 
diagnosis of malaria is imperative for rapid treatment, 
reducing morbidity and mortality, preventing unneces-
sary use of anti-malarials and increased drug resistance 
[2]. As a result, the WHO now recommends that all cases 
of suspected malaria should be confirmed using malaria 
diagnostic tests prior to treatment. Microscopy contin-
ues to be the gold standard for diagnosis of malaria [2] 
but is time and labour intensive, requires qualified per-
sonnel, and is subjective. Rapid diagnostic tests (RDTs) 
have revolutionized the diagnosis of malaria, particularly 
in remote areas [3] but suffer from difficulties in trans-
port and storage, persistence of Hrp-2 in the blood, poor 
detection at very low parasitaemia, and inability to quan-
tify the parasites. Other techniques available for diagno-
sis include immunologic techniques, Polymerase Chain 
Reaction (PCR), Loop-mediated isothermal amplification 
(LAMP), all of which present unique challenges. PCR 
has potential to detect low parasitaemia but is expensive, 
time consuming, and requires highly trained personnel. 
LAMP is being evaluated [4, 5] and is still in early stages 
of development [6].
The SightDx P1 Device aims to overcome these deficits: 
the computer-vision-based technology is designed for 
fast, accurate and cost effective diagnosis of malaria in 
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blood samples. Additionally the device is able to rapidly 
report parasitaemia levels after scanning over 1 million 
red blood cells.
Methods
This trial aimed to evaluate the efficacy of the device, 
as measured by the sensitivity and specificity at differ-
ent levels of parasitaemia. The device was evaluated on 
431 consented patients. Sensitivity and specificity of the 
device were compared against PCR and microscopy. 
Rapid diagnostic tests (RDTs) were used for initial patient 
screening and were also compared against ground truth. 
All patients were symptomatic. The primary endpoint 
was to assess the sensitivity and specificity of the device 
using PCR as the gold standard. The secondary endpoints 
were species identification, accuracy of parasitaemia esti-
mation and comparison with microscopy.
Study design
This was a single center, prospective, non-randomized, 
blinded trial. All technicians were blinded to the results 
of each branch of the study. Comparison between study 
outcomes was done only after data collection and the 
examination was complete.
Study procedures
All patients presenting with fever at the NIMR clinic 
were considered eligible for enrollment and were given 
the option to participate. Informed consent was obtained 
prior to sample collection. Suspected patients for Plas-
modium vivax and Plasmodium falciparum were rou-
tinely diagnosed in the malaria clinic of Wenlock 
Hospital, Mangalore, by examining Giemsa-stained slides 
(and/or malaria RDTs as routinely used in the clinic; SD 
Malaria Ag Pf/Pv in this case). Malaria treatment was 
solely based on the malaria clinic diagnosis process and 
patients’ course of treatment [7] was not changed due to 
the Parasite P1 device or by the NIMR microscopy diag-
noses. In parallel, about 4 µL of blood was collected in 
microfuge tube containing EDTA. These samples were 
scanned onsite by using the P1 device, while P1 final 
analysis was conducted blindly in SightDx’s R&D facil-
ity in Israel. In addition, blood was also collected on filter 
paper spots for PCR evaluation at NIMR, and was used 
for the preparation of two Giemsa-stained smears for 
microscopic examination at NIMR. The Giemsa-stained 
smears and filter papers were transported to NIMR, New 
Delhi.
The Giemsa slides were reviewed by a NIMR microsco-
pist at Wenlock NIMR clinic in Mangalore, and by a sec-
ond microscopist at the NIMR laboratory in New Delhi. 
If there was disagreement between the two reads, or a 
discrepancy in parasitaemia level of greater than 50  %, 
a third microscopist reviewed the slide and made a final 
determination.
Diagnostic  PCR assays were carried out at NIMR. 
For this, DNA was isolated from filter paper using the 
QIAamp mini kit (51306) according to the manufactur-
er’s instructions and stored at −20  °C until PCR could 
be completed. Nested PCR was performed with primers 
described previously [7, 8]. Known positive sample from 
parasite bank of NIMR and previously uninfected indi-
vidual’s blood was used as positive and negative control, 
respectively.
The SightDx digital imaging scanning was performed 
onsite. A blood droplet was stained and diluted in a pro-
prietary solution. This diluted sample was placed inside 
a flow-cell disposable slide. The slide was then loaded 
into the P1 machine where it was scanned automatically. 
Each field was autofocused and stained covering a total of 
270 fields corresponding to 0.2 μl of blood. The complete 
scan took less than 5 min per sample. At peak participant 
volume, 56 patients were analysed in an 8 h working day.
Computer vision and statistical models were used to 
detect the malaria parasites. The algorithm used fluores-
cent cues to detect hotspots and then classified these into 
white blood cells, parasites, or “other”. The algorithm also 
estimated RBC density. Using statistical models, SightDx 
P1 determined infection status, parasitaemia levels, 
and species. Diagnosis and parasitaemia are statistical 
constructs, and there is an Internal Calibration Param-
eter that determines whether a sample is considered 
“negative” that can be adjusted to optimize the tradeoff 
between sensitivity and specificity for the use at hand 
(e.g. screening or confirmation).
Statistical methods
Sensitivity and specificity analysis and 95  % confidence 
intervals (CIs) were computed using a 2 × 2 table for out-
comes of the tested device and the reference outcome. 
Test sensitivity (conditional probability that the test is 
positive if the condition is positive), calculated by the fol-
lowing formula:
Test specificity (conditional probability that the test is 
normal if the condition is normal (negative), calculated 
by the following formula:
Kappa Coefficients were calculated for analys-
ing the agreement between the diagnoses of the two 
Sensitivity = (True Positive)
/
(








True Negative+ False Positive
)
× 100
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microscopists. The data was analysed using the SAS ® 
version 9.1 (SAS Institute, Cary North Carolina).
Results
The SightDx P1 device is a tabletop device for malaria 
diagnostics (Fig.  1). Cartridges are placed in the device, 
scanned and output is presented on the device touch 
screen.
The evaluation of SightDx P1 device performance was 
based on 431 febrile patients reporting to the Malaria 
Clinic at Wenlock Hospital, Mangalore and consent-
ing to participate. Figure  2 shows the description of 
the evaluable samples. Of 431 patients consented to 
participate, 70 samples were not included in the analy-
sis for various reasons: operator errors, such as slide 
placement error, insufficient filling or overfilling of 
the slide (n  =  22), external technical problems, such 
as interruptions during running of the test and power 
failure (n =  3), missing PCR results (n =  5) and sam-
ples marked as undecided by the automated algorithm 
(n  =  40), which need further investigation. These 40 
samples will henceforth be referred to as ‘flagged’ sam-
ples in this article. Thus, the study’s population involved 
361 samples that were evaluated by SightDx device, 
PCR and microscopy.
SightDx compared to PCR and microscopy
The device’s sensitivity and specificity, when compared to 
PCR, were found to be 97.05 % (95 % CI 94.5–99.6) and 
96.33 % (95 % CI 93.7–99.0), respectively.
SightDx sensitivity and specificity compared to 
microscopy were found to be 94.4  % (95  %  CI 90.9–
97.8) and 95.6  % (95  %  CI 92.7–98.6), respectively 
(Table 1).
RDT compared to PCR and microscopy
The RDT’s sensitivity and specificity, when compared 
to PCR, were found to be 93.5  % (95  %  CI 89.8–97.2) 
and 96.3  % (95  %  CI 93.7–99.0), respectively. Sensitiv-
ity and specificity of the RDT compared to microscopy 
were found to be 94.3 % (95 % CI 90.0–97.8) and 96.7 % 
(95 % CI 94.2–99.3), respectively (Table 2).
Speciation
The ability of the device to identify two types of malaria 
species was compared with PCR. The current version 
of the device did not support mixed infection report-
ing. From samples found to be positive by both PCR and 
SightDx, SightDx speciated 73.3  % of PCR P. falcipa-
rum +  samples and 91.4  % of PCR P. vivax +  samples, 
as shown in Table 3. Notably, all of the mixed infection 
samples were positively detected by SightDx as infected. 
Eleven mixed infections were reported as P. vivax, two 
were reported as P. falciparum, while one was reported 
positive.
Parasitaemia
To correlate the microscopists analysis with the para-
sitaemia provided by the SightDx device Pearsons cor-
relation and Spearmans correlation analysis was carried 
out. Spearman’s rank correlation coefficient analysis is 
preferred for monotonic relationships. The Spearman’s 
rank correlation coefficient and the Pearsons correlation 
coefficient calculated when comparing SightDx’s para-
sitaemia reporting to microscopy on infected samples. 
Following the WHO criteria, SightDx was analysed on 
whether or not it produced parasitaemia levels of ±50 % 
of microscopy. Microscopy parasitaemia was considered 
as the average of the two microscopists’ estimation, or 
the third microscopist’s estimation in cases of disagree-
ment. SightDx was within 50 % in 71.3 % of cases (in 117 
out of 164). The overall correlation between the two data 
sets can be seen in Fig. 3.
Discussion
The study evaluates a novel platform for diagnosing 
malaria. It showed sensitivity of 97.5  % and specific-
ity of 96.33  % when compared to PCR. Moreover, the 
study showed that the platform provides high sensitivity 
in cases of low parasitaemia. Going by the WHO stand-
ard of 95  % sensitivity for malaria diagnosis, the device 
has excellent sensitivity. This is the first example of a 
complete vision based malaria diagnostic platform, as 
attempts to develop vision-based device have been made 
in the past with limited success [9–12].
The device was able to speciate 73.3  % of the P. falci-
parum positive samples and 91.4  % of P. vivax positive 
samples compared to PCR. However currently it does not 
Fig. 1 The SightDx P1 Device. A compact platform for malaria 
diagnostics





























Fig. 2 Description of the samples. A total of 431 samples were collected and 361 were analyzed. Removed samples were due to technical errors or 
due to flagged samples
Table 1 Sensitivity and specificity of P1 device versus PCR and microscopy
Comparator Sensitivity Specificity
Percent n/N 95 % CI Percent n/N 95 % CI
Microscopy 94.4 167/177 90.9–97.8 95.6 176/184 92.7–98.6
PCR 97.05 165/170 94.5–99.6 96.33 184/191 93.7–99.0
Table 2 Sensitivity and specificity of RDT versus PCR and microscopy
Comparator Sensitivity Specificity
Percent n/N 95 % CI Percent n/N 95 % CI
Microscopy 94.3 167/177 90.9–97.8 96.7 178/184 94.2–99.3
PCR 93.5 159/170 89.8–97.2 96.3 184/191 93.7–99.0
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detect mixed samples since a large enough database has 
not been collected. There is scope of improvement in this 
area since there are many countries having both the spe-
cies and also have good significant proportion of mixed 
infections [13].
Enumeration of parasites in malaria patients is 
extremely important to know the severity of malaria, as 
a prognostic indicator, drug efficacy studies and clini-
cal trials. Despite availability of various tools for malaria 
diagnosis, microscopy is the mainstay for quantitation of 
parasites. Though accurate, easy to perform, cost effec-
tive, it is labor intensive and can vary between techni-
cians. Very few tools are able to estimate the parasitaemia 
in malaria patients. Real time PCR has the potential to 
quantify parasites and has been proved to be useful [14]. 
Flow cytometry could also accurately measure para-
sitaemia in rodent malaria [9, 10]. Nonetheless, these 
methods need sophisticated equipment and are not cost 
effective. The SightDx P1 platform has a very powerful 
use for quantitative estimation of parasitaemia. It could 
detect the parasite count within 50  % of that detected 
by microscopy in 71.3 % of the cases. Most notably, the 
device demonstrated a correlation coefficient of 0.89 
demonstrating a strong statistical similarity, and convinc-
ingly showing the relevance of the technology in clinical 
malaria assessment.
Strikingly, the test demonstrated significantly improved 
sensitivity and specificity when compared to the RDT 
used in the study. RDTs are known to have poor sensitiv-
ity specifically at low parasitaemia. Moreover, even when 
positive bands do appear, many times they are weak lines, 
which are hard to interpret. While RDTs showed a sen-
sitivity of only 93.5 % the P1 platform showed a sensitiv-
ity of 97.05 %. The SightDx device offers better sensitivity 
and specificity and clearly states whether the sample is 
positive or negative, preventing mis-interpretation or dif-
ficulties in analysis.
Though the device showed good sensitivity and speci-
ficity against PCR, several improvements are still needed. 
The software version used in this study is not equipped 
to detect mixed infections, and while all the mixed infec-
tion samples were diagnosed as infected by the device, 
it interpreted them mostly as P. vivax. Furthermore, the 
device is capable of identifying the infection stage of a 
sample, but verifying the accuracy of infection stage iden-
tification was not in the scope of this study. There were 
operator errors responsible for indeterminate results. 
Such errors could be eliminated by including a modified 
sample-loading mechanism and improved sample-prepa-
ration procedures. The operator errors can be identified 
during the scanning of the sample, in which case, the user 
can be notified to re-run the sample. There were external 
conditions that caused test failures. The device could be 
improved to identify that an interruption has occurred 
and request the user to re-run the sample.
Some samples could not be analysed due to the reasons 
discussed in Fig. 2. However, several software and hard-
ware correction steps were implemented since the data 
collection completion, aiming at dramatically lowering 
the rejection and undetermined sample rate. These steps 
include sample and slide preparation steps to reduce 
overfilling or insufficient slide filling and to improve 
staining solution consistency, slide holding improve-
ments to reduce slide misplacement, software improve-
ments in handling sample deviation and support for 
real-time user re-scan report flag.
Among the 70 rejected samples, reference results were 
available for 64 samples. Three were positive for P. fal-
ciparum, 11 were P. vivax and one was mixed infection. 
Since the device did not provide results for these sam-
ples, they could not be included in the analysis.
CL-IN002 was a single site clinical trial. Multi-site 
studies will help further validating the device. Beyond 
India, future tests sites will be placed throughout Africa, 
South East Asia as well as European areas demonstrating 
non-endemic malaria infections. A diversity of locations 
will further strengthen the device database and demon-
strate the broad ability of the device to diagnosis a variety 
of genetic backgrounds.
Table 3 Speciation accuracy divided according to  treat-
ment groups
SightDx accuracy (%) In numbers 95 % CI
P. vivax 91.4 96/105 86.1–96.8
P. falciparum 73.3 34/46 61.2–86.6

































(parasites per 200 WBCs)
Fig. 3 Correlation between Sight Dx parasitaemia and Microscopy 
parasitaemia. The microscopist counted 200WBCs
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Conclusion
The SightDx P1 device demonstrated a sensitivity of 
97.03 % and a specificity of 96.33 %, significantly exceeding 
the WHO criteria of 95 % accuracy and showing superior 
performance to RDT. Furthermore, since it can evaluate 
speciation and estimate the parasitaemia, it can be a valu-
able tool in clinical practice as well as research studies.
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